ArticleFrontiers in microbiology2025
Molecular characterization of carbapenem resistance mechanisms and phenotypic correlations in clinical
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The purpose of this study is to understand the antimicrobial susceptibility and molecular distribution characteristics of carbapenem-resistant Methods: A total of 150 CRKP collected from January 2019 to December 2021 in the Ningbo region were included in this study. Antimicrobial susceptibility testing was performed using broth microdilution method following CLSI guidelines (CLSI, 2023). The tested agents included: (1) basic antimicrobials (tigecycline, polymyxin B, ceftazidime-avibactam); and (2) combination therapy candidates (ertapenem, imipenem, levofloxacin, piperacillin-tazobactam, ceftriaxone, cefepime, trimethoprim-sulfamethoxazole, fosfomycin, amikacin, aztreonam, chloramphenicol, amoxicillin-clavulanate, ceftazidime). Resistance genes were detected using polymerase chain reaction (PCR). Multi-locus sequence typing (MLST) was employed to analyze the molecular characteristics and evolutionary trends of the strains to determine their clonal relationships. Results: The 150 strains of CRKP exhibit high resistance rates to various conventional drugs; The sensitivity rates to tigecycline, polymyxin B, and ceftazidime-avibactam were 98.7, 98.0, and 68%, respectively; Conversely, the sensitivity rates to fosfomycin, amikacin, and chloramphenicol were 72.0, 40.0, and 16.7%, respectively; The main proportions of carbapemen genes producing in CRKP are as follows: Conclusion: In the region, CRKP showed high sensitivity to tigecycline, polymyxin B, ceftazidime-avibactam, fosfomycin, amikacin, and chloramphenicol. The main carbapenemase genes identified were
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.